Abstract 456P
Background
As mentioned by ESMO guidelines on the management of constipation in advanced cancer, combined opiate/naloxone medications have been shown to reduce the risk of OIC through a range of studies. Oxycodone/naloxone prolonged-release tablets (OXN PR) provide similar efficacy, but an improved bowel function compared with oxycodone prolonged-release tablets (OXY PR). This is the first Chinese study about OXN PR in cancer pain population.
Methods
This multi-center, randomized, double-blind controlled trial compared OXN PR to OXY PR for 4 weeks in adult cancer patients with moderate-to-severe pain and OIC. Primary efficacy endpoints: Bowel Function Index (BFI) and Brief Pain Inventory-Short Form (BPI-SF). Key secondary endpoints: use of laxative (bisacodyl tablets) and rescue analgesia (morphine sulfate), quality of life (EQ-5D) and safety.
Results
232 patients were randomized (117 in the OXN PR group; 115 in the OXY PR group). BPI-SF average pain was comparable after 4 weeks between OXN PR and OXY PR groups. The difference of average BFI at 4 weeks was not statistically significant between the 2 treatment groups (FAP, p=0.482). Compared to baseline, a BFI reduction was seen after 1 week in OXN PR group (13.5 points vs. 8.8 points in OXY PR group; p=0.039). Results of an exploratory post-hoc analysis confirmed these findings, with the BFI difference favoring OXN PR. Laxative use was similar between the 2 groups, but a higher percentage of patients required laxatives in OXY PR group compared to OXN PR group at all visits. Average daily dose and percentage of patients taking rescue analgesia were similar at 4 weeks. EQ-5D assessment showed a minor improvement in the OXN PR group and a decline in OXY PR group (non-significant). Fewer adverse events were reported in the OXN PR group (17.5% vs. 27.0% in the OXY PR group); No treatment-related SAEs were reported with OXN PR group.
Conclusions
In managing moderate-to-severe cancer pain among Chinese patients, OXN PR has demonstrated comparable efficacy to OXY PR. Improvements of bowel function were numerically observed and statistically confirmed by a post-hoc analysis (p=0.039). This study adds to the wealth of evidence around the positive benefit/risk profile of OXN PR in an Asian population.
Clinical trial identification
NCT00513656.
Editorial acknowledgement
Editorial assistance was provided by MedAcc Technology Co., Ltd.
Legal entity responsible for the study
Mundipharma (China) Pharmaceutical Co.LTD.
Funding
Mundipharma (China) Pharmaceutical Co.LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract